Login to Your Account



Genelabs' Prestara Again In Trouble, This Time In Taiwan

By Karen Pihl-Carey


Friday, April 8, 2005
The path to market for Genelabs Technologies Inc.'s lupus drug Prestara narrowed this week when another Phase III trial failed to meet the primary endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription